256 Participants Needed

Effects of a Yeast Fermentate (EpiCor) Supplement on Cold or Flu Symptoms in Healthy Children

AC
ME
Overseen ByMalkanthi Evans, PhD

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if participants must stop taking their current medications, but it asks participants to maintain their current lifestyle habits, including medications, as much as possible.

Is there any safety data available for the treatment known as EpiCor, Placebo, Control, or Dummy Treatment?

Placebo treatments, often used as controls in clinical trials, have been studied for their safety and effectiveness across different diseases. However, reports on adverse events (unwanted side effects) in these trials are often incomplete or inconsistent, indicating a need for better reporting to fully understand their safety profile.12345

What is the purpose of this trial?

This trial tests if taking EpiCor daily for about three months can reduce cold or flu symptoms in children aged 4-12 who go to school or daycare. EpiCor is a supplement that may help boost the immune system.

Research Team

DC

David Crowley, MD

Principal Investigator

KGK Science

Eligibility Criteria

Inclusion Criteria

The child and the child's parent(s) or legal guardian(s) have given voluntary, written, informed consent to partake in the study
Males and females between the age of 4-12 years of age, inclusive
Individuals of child-bearing potential must have a negative baseline urine pregnancy test
See 5 more

Exclusion Criteria

Participation in a clinical research trial within 30 days prior to randomization, as assessed by the Qualified Investigator
Participant or participant's caregiver who are cognitively or neurodevelopmentally impaired and/or are unable to give informed consent
Participants with siblings that live in the same household and are eligible for the study unless they are enrolled consecutively (e.g., not enrolled at the same time)
See 8 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person)

Run-in

Participants complete the CARIFS questionnaire and study diary during the run-in period

2 weeks
No visits

Treatment

Participants receive daily oral EpiCor or placebo supplementation for 84 days

12 weeks
3 visits (in-person) at day 0, day 42, and day 84

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • EpiCor
  • Placebo
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: EpiCorExperimental Treatment1 Intervention
500 mg EpiCor given as two gummy supplements. Participants will be instructed to take two gummies per day in the morning, with or without food, for 84 days, starting on Day 1.
Group II: PlaceboPlacebo Group1 Intervention
Two gummy supplements. Participants will be instructed to take two gummies per day in the morning, with or without food, for 84 days, starting on Day 1.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Cargill

Lead Sponsor

Trials
28
Recruited
3,200+

KGK Science Inc.

Industry Sponsor

Trials
82
Recruited
6,400+

Najla Guthrie

KGK Science Inc.

Chief Executive Officer since 1997

Research career at the Centre for Human Nutrition, University of Western Ontario

Dr. Bibiane Zakaria

KGK Science Inc.

Chief Medical Officer since 2023

MD from an unspecified institution

Findings from Research

A systematic review of 80 randomized controlled trials (RCTs) on noninvasive analgesic treatments revealed that adverse event (AE) reporting was often incomplete, with over 40% of trials not reporting any serious adverse events.
The review highlighted that trials involving participants with pain conditions and those sponsored by industry provided better AE data, indicating a need for improved consistency and thoroughness in AE reporting across all analgesic RCTs.
Adverse event assessment, analysis, and reporting in recent published analgesic clinical trials: ACTTION systematic review and recommendations.Smith, SM., Wang, AT., Katz, NP., et al.[2023]
A new checklist called TIDieR-Placebo has been developed to improve the reporting of placebo or sham interventions in clinical trials, ensuring that researchers clearly describe these components alongside active treatments.
The checklist was created through expert consultation and aims to enhance the transparency of trial results, which is crucial for accurately assessing the benefits and harms of active interventions.
TIDieR-Placebo: A guide and checklist for reporting placebo and sham controls.Howick, J., Webster, RK., Rees, JL., et al.[2020]
The study systematically analyzed placebo effects from randomized, placebo-controlled trials, revealing that while placebos can influence clinical symptoms, they do not affect laboratory values like blood glucose in diabetics.
Placebo side effects were found to be similar to those of active treatments, highlighting the importance of careful placebo use in clinical research to ensure patient safety and informed consent.
Placebo treatment is effective differently in different diseases--but is it also harmless? A brief synopsis.Weihrauch, TR.[2019]

References

Short-term effects of dry needling of thenar muscles in manual laborers with carpal tunnel syndrome: a pilot, randomized controlled study. [2023]
Adverse event assessment, analysis, and reporting in recent published analgesic clinical trials: ACTTION systematic review and recommendations. [2023]
TIDieR-Placebo: A guide and checklist for reporting placebo and sham controls. [2020]
Placebo treatment is effective differently in different diseases--but is it also harmless? A brief synopsis. [2019]
The mechanical effect of kinesiology tape on rounded shoulder posture in seated male workers: a single-blinded randomized controlled pilot study. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security